BLUEJETBlue Jet Healthcare Ltd.
Blue Jet Healthcare Q2 FY27 Results: Standalone Net Profit ₹103 Crore on Total Income of ₹402 Crore
- Earnings
- Pharmaceutical intermediates
Reviewed byKeshav SehgalBlacklitt Research
Blue Jet Healthcare (NSE: BLUEJET) reported total income of ₹401.95 crore and net profit of ₹102.52 crore for the quarter ended 30 Sep 2026, on a standalone basis, it said in a filing on 05 Nov 2026. The company has no subsidiaries, so no consolidated figures are reported.
Key highlights
Standalone
The company on its own, without its subsidiaries
- Total income: ₹401.95 crore, up 111.8% YoY and 30.4% QoQ
- Net profit and EPS: ₹102.52 crore, up 96.6% YoY; basic EPS ₹5.46 against ₹3.01
- Finance costs: ₹0.64 crore, down from ₹4.63 crore a year earlier
- Other income: ₹26.21 crore, up 8.0% YoY and 72.0% QoQ
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 401.95 | 189.75 | +111.8% | 308.35 | +30.4% | |
| Revenue from operations | 375.74 | 165.48 | +127.1% | 293.11 | +28.2% |
| Other income | 26.21 | 24.27 | +8.0% | 15.24 | +72.0% |
| 102.52 | 52.14 | +96.6% | 78.26 | +31.0% | |
| Profit before tax | 137.39 | 68.73 | +99.9% | 105.95 | +29.7% |
| Finance costs | 0.64 | 4.63 | -86.1% | 0.66 | -2.9% |
| Depreciation | 6.92 | 5.87 | +18.0% | 6.71 | +3.2% |
| Tax expense | 34.88 | 16.59 | +110.2% | 27.68 | +26.0% |
| Net profit margin | 25.50% | 27.48% | -1.97 pp | 25.38% | +0.12 pp |
| EPS, basic (₹) | 5.46 | 3.01 | +81.4% | 4.51 | +21.1% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Income grew much faster than the year-earlier quarter, and revenue from operations drove most of it. Revenue from operations rose 127.1% to ₹375.74 crore, while other income rose 8.0% to ₹26.21 crore, so other income was 6.5% of total income this quarter.
Net profit grew more slowly than income. Net profit rose 96.6% YoY against 111.8% for total income, and the net profit margin fell to 25.50% from 27.48%. Tax expense rose 110.2% to ₹34.88 crore, which is 25.4% of profit before tax of ₹137.39 crore.
Finance costs fell to ₹0.64 crore from ₹4.63 crore a year earlier, which is 0.2% of total income this quarter. The filing does not give the reason for the fall. Other income is 19.1% of profit before tax, and the filing does not give the reason for its rise.
Against the previous quarter, net profit rose 31.0%, slightly faster than total income at 30.4%. Depreciation rose 3.2% QoQ to ₹6.92 crore. The company describes a single reportable business segment, manufacturing artificial sweetener, contrast media intermediate, pharma intermediate and APIs.
Inference
The company allotted 1,58,10,276 equity shares to qualified institutional buyers at ₹506 per share, aggregating ₹800 crore under a Qualified Institutional Placement. Paid-up equity capital rose to ₹37.86 crore from ₹34.69 crore a year earlier, and share issue expenses of ₹19.39 crore were paid in the six months to 30 Sep 2026.
Equity dividend paid in the six months was ₹22.71 crore, with none in the prior-year period. The filing does not say how the QIP proceeds will be used, and it does not give a reason for the large rise in investments and cash balances after the QIP.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
